Ilana Wisby spent seven years turning an Oxford University spinout into a company capable of deploying 32-qubit quantum systems into commercial data centres. This week she joined Cambridge Innovation Capital not to raise another fund, but to sit inside the firm's Entrepreneurs in Residence programme, embedding herself in early-stage intellectual property projects before they have found a name, a board or a business model. It is a quiet appointment, easily filed under routine deep tech news. It should not be read that way inside the Department of Health and Social Care.

The problem CIC is trying to solve with this hire is the same problem that has quietly defeated three successive NHS life sciences strategies. Britain does not lack research. Its universities produce world-class intellectual property in quantum computing, genomics, diagnostics and AI at a rate that continues to outstrip most of Europe. What it lacks, consistently and expensively, is the operator expertise needed to carry that research from a laboratory paper into something a health system can actually procure. Wisby's move is an admission that capital alone does not close that gap. What closes it is someone who has already built the thing once, sitting next to the people trying to build it for the first time.

This matters to the NHS for a reason that goes beyond quantum computing itself, which has no near-term clinical application worth pretending otherwise about. It matters because the same translation failure that stalls British deep tech is the reason NHS trusts so often end up buying mature capability from American vendors rather than nascent capability from British ones. Palantir did not win the Federated Data Platform contract because no comparable British expertise existed. It won because British expertise, where it existed, had rarely been carried far enough down the commercialisation path to be procurable at NHS scale by the time a tender was issued. The pattern repeats across diagnostics, imaging AI and increasingly ambient voice technology now working its way through MHRA approval. Good research, thin bridge, foreign vendors fill the space where a British company should have stood.

Government life sciences strategy has tended to treat this as a funding problem, and successive announcements of capital for spinouts have followed accordingly. Sir Jim Mackey's centralising instincts inside NHS England, and now DHSC directly, have if anything sharpened the incentive to buy proven systems off the shelf rather than gamble on domestic ones still finding their commercial footing. That is a rational institutional response to operational pressure, but it hardens a cycle in which British-originated technology matures abroad or inside foreign-owned platforms before it returns to the NHS as an import.

Compared to other public strategy publications, CIC's EIR model provides a more accurate diagnosis. It does not promise that more money automatically produces more companies. It backs the judgment that the scarce resource is people who have already navigated the specific, unglamorous steps between a research paper and a functioning commercial product, and that this judgment is worth more at the earliest stage than at the point when a later-stage investor writes a cheque.

There is no obvious mechanism for DHSC or NHS England to replicate a venture capital EIR programme directly, and it would be a mistake to pretend otherwise. But the logic travels further than the quantum sector. Any serious attempt to reduce NHS dependency on a small number of large external vendors will need something functionally similar: experienced operators embedded early enough in British health-tech development to get products to a state where NHS procurement can actually choose them, rather than defaulting again to whichever platform already exists at scale elsewhere.

Wisby's appointment will not register as health policy news. It should register as a reminder of where the real bottleneck sits, and why simply announcing more capital for life sciences, as governments have done repeatedly without visible effect on NHS vendor dependency, has not been enough to change it.